Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study

Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study

Background Most systemic agents used for moderate-to-severe atopic dermatitis (AD) may lead to adverse events requiring routine laboratory monitoring, increasing patient burden and possibly decreasing treatment adherence. Objective To evaluate clinical laboratory findings in adults with moderate-to-...

Full description

Bibliographic Details
Main Authors: Lisa A. Beck, Diamant Thaçi, Mette Deleuran, Marjolein de Bruin-Weller, Zhen Chen, Faisal A. Khokhar, Meng Zhang, Zafer E. Ozturk, Brad Shumel
Format: Article
Language:English
Published: Taylor & Francis Group 2022-04-01
Series:Journal of Dermatological Treatment
Subjects:
dupilumab
laboratory
safety
long-term
open label
clinical trial
Online Access:http://dx.doi.org/10.1080/09546634.2020.1871463

Internet

http://dx.doi.org/10.1080/09546634.2020.1871463

Similar Items